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Cyclooxygenase-2–selective inhibitors impair glomerulogen- glandins in renal development. These renal abnormali-
esis and renal cortical development. ties range from oliguria to renal dysgenesis and have
Background. Antenatal exposure to nonsteroidal anti-inflam- been seen particularly when NSAIDs were administeredmatory drugs (NSAIDs) has been associated with renal dysgen-
before the 32nd week of gestation [1, 2]. Similar findingsesis in humans.
were observed in offspring of rhesus monkeys treatedMethods. These studies characterized cyclooxygenase-2
(COX-2) versus COX-1–selective inhibition on nephrogenesis with indomethacin during gestation [3]. Avner and co-
in the rodent using histomorphometry, immunohistology, and workers showed that prostaglandin E1 (PGE1) is neces-
in situ hybridization. sary for maximal growth and differentiation of meta-Results. Administration of a COX-2–selective inhibitor
nephroi in culture [4]. Taken together, these data suggest(SC58236), started during pregnancy until weaning, signifi-
an important role for cyclooxygenase (COX)-mediatedcantly impaired development of the renal cortex and reduced
glomerular diameter in both mice and rats. An identical pheno- prostaglandin formation in renal development.
type was demonstrated in COX-2 2/2 mice. In contrast to its Two isoforms of COX are known to exist. COX-1 is
effects on the developing kidney, a COX-2 inhibitor had no expressed constitutively and considered a housekeeping
effect on glomerular volume in adult mice. This effect was
gene, having important roles in the maintenance of epi-specific for COX-2 because maternal administration of a COX-
thelial integrity. COX-2 was identified as an immediate1–selective inhibitor (SC58560) did not affect renal develop-
ment despite significantly inhibiting gastric mucosal prostaglan- early-response gene, up-regulated in fibroblasts treated
din E2 (PGE2) synthesis in pups. The expression of COX-2 with tumor-promoting phorbol esters [5]. COX-2 is not
immunoreactivity peaked in the first postnatal week and was constitutively expressed in many tissues and is only ob-
localized to S-shaped bodies and the macula densa in the cortex.
served after they are exposed to cytokines and growthTreatment with a COX-2 inhibitor during this period (from
factors. However, COX-2 is expressed constitutively inpostnatal day 0 to day 21) severely reduced glomerular diame-
fetal and adult kidney in all species examined [6–9]. Geneter, whereas treatment limited to pregnancy did not affect
glomerular size. knockout studies show that COX-1 disruption does not
Conclusion. These data demonstrate an important role for interfere with normal renal development [10]. In con-
COX-2 activity in nephrogenesis in the rodent, and define a trast, COX-2–deficient mice exhibit renal dysgenesis as-specific time period of susceptibility to these effects.
sociated with hypoplastic glomeruli [11, 12]. These struc-
tural renal abnormalities in COX-2 null mice have not
been quantitatively defined. Furthermore, the effect ofReports of renal dysgenesis in newborns of women
COX-2 disruption on renal morphology in the adulttreated with nonsteroidal antiinflammatory drugs
could not be separated from the earlier effects on the(NSAIDs) during pregnancy suggest a role for prosta-
neonate. Recently, COX-2–selective NSAIDs have be-
come widely available for clinical use as antiinflamma-
tory analgesics. It has been argued that these inhibitorsKey words: cyclooxygenase, NSAIDs, nephrogenesis, prostaglandins,
macula densa. might not cause the same renal changes seen in COX-
2–deficient mice, which might rather be due to compen-Received for publication July 7, 1999
satory changes in other biologic pathways resulting fromand in revised form September 1, 1999
Accepted for publication September 28, 1999 COX-2 gene disruption or interference with a single
event at a critical time in development [13, 14]. TheÓ 2000 by the International Society of Nephrology
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purpose of these studies was to determine whether or not stranded cDNAs using Moloney murine leukemia virus
reverse transcriptase and 2.5 mmol/L of random primersthe administration of COX-2 isoform-selective NSAIDs
cause renal abnormalities in developing and adult mice according to manufacturer’s instructions (GeneAmp
RNA PCR kit; Perkin Elmer Cetus, Norwalk, CT, USA).and rats, and compare these effects to those in COX-2
2/2 mice. Polymerase chain reaction (PCR) was carried out using
selective primers (10 pmol each primer), 2.5 U Taq DNA
polymerase (Stratagene, La Jolla, CA, USA) in a 20 mL
METHODS
final reaction volume containing 2 mmol/L MgCl2, 60
Animals mmol/L KCl, 12 mmol/L Tris-HCl, pH 8.3. The COX-2
upstream primer was 59 CAG AAG GCA ATG TTCC57 Bl/6 J mice were obtained from The Jackson Lab-
oratory (Bar Harbor, ME, USA), and Sprague Dawley TTG AAC 39, and the downstream primer was 59 CAA
TCC CTG ACA TGG 39. Amplification products wererats (Harlan Bioproducts for Science Inc., Indianapolis,
IN, USA) were used to produce timed pregnancies. analyzed by 2% agarose gel electrophoresis and ethid-
ium bromide staining. Fragments were cloned intoNoon of the sperm-positive morning was designated as
embryonic day 0.5 (E0.5); the day of birth was designated pBluescript (SK-; Stratagene) and identified by dideoxy
sequencing. Sequence data were obtained from Gen-postnatal day 0 (P0). Offspring from C57 Bl/129 Ptgs 2
2/1 were genotyped as outlined previously [11]. The Bank (http://www.ncbi.nlm.nih.gov).
isozyme-specific COX inhibitors SC58560 (COX-1) and
ImmunoblottingSC58236 (COX-2) were kindly provided by Drs. P.C.
Isakson and K. Seibert (Monsanto Searle, St. Louis, MO, Kidneys were homogenized in 30 mmol/L Tris (hydro-
xymethyl)aminomethane (Tris) hydrochloride, pH 8.5,USA). For studies in mice, the compounds were diluted
to a final concentration of 0.6 mg/L (SC58236) and and 100 mmol/L phenylmethylsulfonylfluoride (PMSF).
Following a 10-minute centrifugation at 10,000 3 g, the3 mg/L (SC58560) in tap water with 0.01% Tween and
0.2% polyethylene glycol 200 (PEG 200) as solvents. supernatant was centrifuged at 100,000 3 g to prepare
microsomes as described previously. Microsomes wereThe administration of the drugs was initiated at E0.5 or
P0. Blood levels of the drug were determined by high- harvested in sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) sample buffer [120performance liquid chromatography at Searle/Monsanto
(kindly performed by Drs. Jerry Muhammed and Peter mmol/L Tris-HCl, pH 6.5, 4% SDS, 5 mmol/L dithi-
othreitol (DTT), and 20% glycerol] followed by repeti-Isakson). For studies on pregnant rats, daily gavage of
SC58236 in methylcellulose vehicle (10 mg/kg body wt/ tive aspiration. This material was then heated in boiling
water for three minutes, and the protein concentrationday) was begun on E10.5 and was continued through
weaning. was determined. Twenty milligrams of each protein ex-
tract were loaded onto a 10% SDS-PAGE mini-gel and
Quantitation of prostaglandin E2 synthesis in run at 200 V. After transfer to nitrocellulose membrane
gastric mucosa (100 V, 1 h, 48C), the membrane was washed three times
with TBST (50 mmol/L Tris, pH 7.5, containing 150Mucosal linings of stomachs from control and experi-
mental animals were harvested and frozen in dry ice. mmol/L NaCl, 0.05% Tween 20) and then incubated in
blocking buffer (TBST containing 5% Carnation nonfatTissue was homogenized in 0.1 sodium phosphate buffer
containing 15% methanol. Samples were centrifuged at dry milk) for one hour at room temperature. The nitro-
cellulose membrane was then incubated in primary anti-12,000 r.p.m. at 48C in a tabletop centrifuge. Superna-
tants were passed through a C-18 column (Waters, Mil- body (COX-1, Santa Cruz, C-20; COX-2, Cayman,
160106) diluted 1:300 and 1:1000 in blocking buffer over-ford, MA, USA) preconditioned with 2 mL of methanol
followed by 2 mL of water. C-18 columns were washed night at 48C. Following washing, the membrane was incu-
bated with horseradish-peroxidase–labeled secondarywith H2O/methanol (97/3), H2O, and hexane. PGE2 was
eluted in 1 mL of ethylacetate. The solvent was evapo- antibody (1:20,000; Vector Lab., Inc., Burlingame, CA,
USA) for one hour and was washed in TBST, and label-rated under a stream of nitrogen and dissolved in 500
mL of extraction buffer. PGE2 content in gastric mucosa ing was visualized with chemiluminescence reagent (Du-
Pont NEN, Boston, MA, USA) exposing the membranewas determined by enzyme immunosorbent assay (EIA)
(PGE2 enzyme immunoassay kit; Oxford Biomedical Re- to Kodak XAR-5 film.
search Inc., Oxford, MI, USA).
Micrography and quantitative image analysis
Reverse transcription-polymerase chain reaction Photomicrographs were viewed with a Zeiss Axioskop
microscope using either bright field or dark-field opticsTotal RNA was purified from mouse neonatal kidney
using TRIZOL-REAGENTe (GIBCO BRL, Grand Is- (Micro Video Instruments, Avon, MA, USA). Pictures
were captured with a digital camera (Spot-Cam; Diag-land, NY, USA) and reverse transcribed to single-
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Fig. 1. Reduced cortical volume in COX-2 inhibitor and COX-2 2/2 mice. Mouse kidneys were harvested at P21 and stained with hematoxylin
(A–D). Compared with control kidneys (A) and kidneys from mice treated with a COX-1 inhibitor (B), low-power magnifications of coronal
kidney sections reveal a reduced cortical volume in COX-2 inhibitor-treated mice (C ) and COX-2 2/2 mice (D). Rat kidney sections (E and F)
were stained with an anti lipocortin antibody, which highlight glomeruli (brown). A similar reduction in cortical volume is seen in rats treated
with the COX-2 inhibitor (F ) compared with control kidneys (E).
nostic Instruments, Sterling Heights, MI, USA), and and sense riboprobes from mouse COX-2 (597 bp) were
hybridized to tissue sections and washed as previouslycolor composites were generated by using Adobe Pho-
toshop v4.0 on a Power Macintosh. The diameter of described [6]. Slides were then dipped in emulsion (Ilford
K5; Knutsford, Cheshire, England, UK) diluted 1:1 withglomeruli was measured perpendicularly to the renal
capsule using BIOQUANT (R&M Biometrics, Nash- 2% glycerol and exposed for four to five days at 48C.
After developing in Kodak D-19, slides were counter-ville, TN, USA). Three coronal kidney sections from
three individual animals from each group were analyzed. stained with hematoxylin.
ImmunohistochemistryIn situ hybridization
Mouse tissue was fixed in 4% paraformaldehyde over- Mouse tissue was fixed in 4% paraformaldehyde over-
night and embedded in paraffin. Sections were cut atnight and embedded in paraffin. 35S-labeled antisense
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inhibitor markedly reduced renal cortical volume, as
seen on low-power views of kidneys at P21 compared
with control kidneys (Fig. 1 A, C). No overt effect on
kidney morphology is seen in animals treated with the
COX-1 inhibitor (Fig. 1B). Similarly, P21 kidneys from
COX-2 2/2 mice (Fig. 1D) showed reduced cortical
volume despite maintaining normal papillary volume.
Similar findings were observed in rats treated with
SC58236 from E10.5 (inception of metanephric develop-
ment) to P15 (Fig. 1 E, F).
Impaired renal cortical development in mice was ac-
companied by reduced mean glomerular cross-sectional
diameter from 47.01 6 0.41 mm in controls to 29.35 6
0.42 mm in COX-2 inhibitor-treated mice (P , 0.0001
vs. control, N 5 411; Fig. 2). This decrease was identical
to that seen in COX-2 2/2 mice in which the glomerular
diameter was 29.35 6 0.68 mm (P , 0.0001 vs. control,Fig. 2. Histologic analysis and histomorphometry of renal cortical de-
velopment in control and experimental animals. The mean glomerular N 5 320). Glomerular cells were more densely packed,
diameter was determined in control, COX-1– or COX-2–selective inhib- and podocytes within cortical glomeruli of COX-2 inhibi-itors treated mice, and in COX-2 2/2 mice. In control animals and
tor-treated animals (Fig. 3E) and COX 2/2 mice wereCOX-1 inhibitor (SC58560)-treated mice, the mean glomerular diame-
ter was similar, whereas it was significantly reduced by the COX-2 cuboidal, whereas podocytes within subcapsular glomer-
inhibitor (SC58236) either from conception to P21 or from P0 to P21. uli from control (Fig. 3F) mice were flattened. The ad-*P , 0.00001 compared with control values.
ministration of SC58236 also reduced glomerular diame-
ter in developing rat kidney treated from E10.5 to P15.
Even after perfusion fixation of rat kidneys and expan-
sion of rat glomeruli, the diameter was significantly re-
4 mm thickness, dewaxed in xylenes, and incubated for duced from 54.11 6 0.87 mm in control rats versus 51.16 6
30 minutes in methanol containing 0.3% H2O2 to block 0.32 mm in SC58236-treated animals (control, N 5 125;
endogenous peroxidase activity. Sections were then mi- experimental, N 5 1441, P , 0.01). The small glomeruli
crowaved for three minutes in PBS containing 0.1 mol/L did not represent a complete failure of glomerulogenesis
sodium citrate. Primary antibody was diluted 1:200 in because glomeruli from SC58236-treated rat pups were
TBST containing 1% bovine serum albumin (BSA) and positive for factor VIII staining (endothelial cells) and
1% nonfat dry milk. The antibodies were visualized using Thy 1.1 staining (mesangial cells; data not shown). Fur-
Vector Stain Elite and counterstained with hematoxylin. thermore, erythrocytes were present in the small glomer-
For rat tissue, rats were exsanguinated under deep anes- uli of nonperfused mouse kidneys. Tubules in the imme-
thesia with 50 mL/100 g heparinized saline (0.9% NaCl, diate subcapsular area were reduced in volume in COX-2
2 U/mL heparin, 0.02% sodium nitrite) through a trans- inhibitor-treated mice.
cardiac aortic cannula and fixed with glutaraldehyde- To determine the stage of renal development affected
periodate acid saline (GPAS), as described previously by the COX-2 inhibitor, we limited treatment of mice
[6]. Following dehydration with a graded series of etha- with SC58236 to P0 through P21 (0.6 mg/L SC58236 in
nol and embedding in paraffin, immunostaining was per- the drinking water). Plasma levels for the COX-2 inhibi-
formed as described previously in this article. tor were 18 and 8 mg/L for mother and pups, respectively.
A similar but less pronounced reduction in glomerular
diameter (22%) was observed in mice in which COX-2RESULTS
inhibitor treatment was limited to the postnatal period
Effects of COX-1 and COX-2 inhibitors on (37.31 6 0.68 mm vs. 47.01 6 0.67 mm in control, P ,
renal development 0.0001, N 5 350; and P , 0.0000001 vs. E0.5 to P21;
The effects of pharmacologic inhibition of COX-1 ver- Fig. 3A). In contrast, when SC58236 was limited to the
sus COX-2 on murine kidney development were investi- gestational period and stopped at P0, no effect on glo-
gated by treating pregnant mice from E0.5 (morning of merular diameter was appreciated (47.1 6 0.65 mm in
the sperm positive day) with the COX-2 inhibitor experimental animals). Thus, postnatal murine renal de-
SC58236 or the COX-1 inhibitor SC58560 until P0 or velopment is most sensitive to COX-2 inhibition.
weaning at P21. At P0, no effects on renal morphology Initial inspection suggested that COX-2 inhibition did
were observed in either COX-1 or -2 inhibitor-treated not affect juxtamedullary glomerular size. This impres-
sion was morphometrically confirmed. The juxtamedul-mice or in COX-2 2/2 mice. Treatment with the COX-2
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Fig. 3. Histologic analysis and histomorphometry of renal cortical development in control and experimental animals at postnatal day 21. Kidney
sections from control and experimental animals at P21 were stained with hematoxylin. In control animals, cortical glomeruli exhibit a mature
morphology, but they are still smaller in size compared with juxtamedullary glomeruli at P21 (A). A similar pattern is observed in animals treated
with the COX-1 inhibitor (B). Up to three layers of tubules occupy the space between the subcapsular glomeruli and the renal capsule. (C) In
COX-2 inhibitor-treated animals, subcapsular glomeruli exhibit greatly reduced size. The urinary space of Bowman’s capsule was increased. In
addition, the outermost layer of tubules appears thinned and immature. (D) A phenotype similar to mice treated with the COX-2 inhibitor
including immature tubules and minuscule cortical glomeruli is seen in COX-2 2/2 mice. Podocytes within cortical glomeruli from controls are
flattened (E; arrows), whereas podocytes within subcapsular glomeruli of COX-2 inhibitor-treated mice (F; arrows) are cuboidal.
lary glomeruli diameter was 47.11 6 0.56 mm and un- cortex and medulla did not exhibit detectable changes
following treatment with the COX-1 inhibitor (Fig. 3B).changed by the COX-2 inhibitor (46.59 6 0.38 mm, not
significant vs. control) and slightly larger in COX-2
Effects of COX-1–selective inhibitors on gastric
2/2 mice (49.71 6 0.59 mm, P , 0.05, N 5 170). mucosal prostaglandin E2 synthesisThe effect of the COX-2 inhibitor was also tested in
Because renal cortical development was not affectedadult mice (12 weeks of age). The administration of
by administration of the COX-1–selective inhibitor, weSC58236 (0.6 mg/mL) 312 weeks did not affect mean
assessed drug transfer from the mother to the pups by
glomerular cross-sectional diameter: 48.9 6 0.63 mm in measuring COX-1 dependent PGE2 synthesis in the gas-
controls vs. 50.02 6 0.59 mm (N 5 230) in experimental tric mucosa of the pups [13]. Maternal SC58560 treat-
animals. No difference in glomerular diameter was ob- ment reduced gastric PGE2 synthesis in the pups by 86%,
served in mice treated with the COX-1 inhibitor SC58560 from 4.98 ng/mg 6 0.93 protein of mucosal tissue in
throughout gestation and postnatal development (47.66 6 control pups, to 0.58 ng/mg protein 6 0.64 of mucosal
tissue in SC58560-treated pups (P , 0.05, N 5 3).0.43 mm, P , 0.0001, N 5 310; Fig. 2). Likewise, the renal
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Fig. 4. (A) Expression of COX-2 protein in total kidney microsomes during postnatal renal development (P0–P21) up to P56. (Right upper panel)
Expression of COX-1 protein increases from P0 to P4 and then is expressed at constant levels. Data represent pooled membranes from three mice
at each time point. This experiment was repeated twice. (Lower panel) Expression of COX-2 protein increases from P0 to P4 and then declines
rapidly to undetectable levels at subsequent time points. (B) Treatment with the COX-2 inhibitor induces expression of COX-2 in renal microsomes.
Renal microsomes from neonatal mice exposed in utero to the COX-2 inhibitor were analyzed for expression of COX-1 and COX-2 immunoreactive
protein. Expression of COX-1 was unchanged. Compared with expression of COX-2 protein in control microsomes, COX-2 is greatly increased
in experimental animals.
Expression and intrarenal localization of COX-2 in within and adjacent to the macula densa, consistent with
its up-regulation by immunoblot and supporting the indeveloping and adult mouse
situ hybridization data.The expression of COX-1 and COX-2 protein during
murine renal development was examined by immunoblot
(Fig. 4). COX-2 protein expression increased from P0 DISCUSSION
to P4 and then declined. Selectivity of the antibodies The adult kidney is a major site of prostaglandin syn-
used in this study was confirmed by stripping the mem- thesis and action. Prostaglandins regulate a wide variety
branes and reprobing with COX-1–selective antibodies. of renal functions, including glomerular and renal medul-
COX-1 protein expression also increased from P0 to P4 lary blood flow, renin secretion, and salt and water trans-
but then remained constant during later stages of kidney port in thick limb and collecting duct [16]. There is also
development and adult life. Mice treated in utero with evidence that prostaglandins are synthesized in the kid-
the COX-2 inhibitor exhibited a marked up-regulation ney during fetal and early postnatal life [17]. Targeted
of renal COX-2 protein at P0, supporting transplacental disruption of the gene encoding COX-2 suggests an im-
drug transfer (Fig. 4B). In contrast, the expression of portant role for the COX-2 protein in nephrogenesis;
COX-1 protein at P0 was not changed. however, the precise structural changes in this model
In situ hybridization in developing mouse kidneys lo- remain uncharacterized [11, 12].
calized COX-2 mRNA to tubular epithelial cells derived These present studies now extend these findings, dem-
from the induced mesenchyme of the developing neph- onstrating that COX-2– but not COX-1–selective
ron and interstitial cells of the renal medulla. COX-2 NSAIDs also disrupt nephrogenesis, and for the first
mRNA expression was detected in renal vesicles, the time to our knowledge define a discrete effect of COX-2
earliest epithelial structure derived from the induced inhibition on glomerular size. The finding that COX-2
metanephric mesenchyme [15]. COX-2 mRNA expres- inhibitors impair renal development in both mice and
sion predominated in developing tubule epithelial cells rats argues against a species- or strain-specific effect of
adjacent to nascent glomeruli (Fig. 5A), and COX-2 ex- COX-2 inhibitors attributable to modifier loci or genetic
pression was detected in comma- and S-shaped bodies. background. This newly described effect of COX-2 inhib-
In mature glomeruli, COX-2 mRNA is expressed in cells itors on glomerulogenesis was quantitatively identical to
associated with the macula densa. No labeling of podo- that we observed in transgenic COX-2 2/2 mice. The
cytes or the parietal layer of Bowman’s capsule was seen. small subcapsular glomeruli also appear immature, as
A prominent hybridization to juxtamedullary macula judged by the presence of cuboidal shaped podocytes
densa was observed as early as E14.5 and was also pres- in cortical glomeruli [18]. Furthermore, the subcapsular
ent in superficial cortical nephrons of adult kidneys (Fig. layer of tubules was thinned, and the tubular diameter
5B). COX-2 immunostains of sections from control ani- was reduced. It remains to be determined whether or
mals were unsuccessful; however, COX-2 immunoreac- not this change in nephron development is secondary to
tivity was detected (Fig. 5C) in kidneys from animals the glomerular defect or an independent direct of effect
of COX-2 inhibition on nephron growth.treated with a COX-2 inhibitor and localized to cells
The period during which COX-2 inhibitors interfere
with glomerulogenesis was partially defined by studies
examining their effects at different time periods during
development. Limiting COX-2 inhibitor treatment to
gestation (that is, stopping at birth) did not yield overt
effects on kidney morphology examined at P21. In con-
trast, treatment with the COX-2 inhibitor throughout
gestation to P21, or treatment from P0 to P21, resulted
in severe impairment of the development of cortical glo-
meruli. Interestingly, animals treated throughout preg-
nancy had significantly smaller glomeruli than those in
which SC58236 treatment started at P0. This supports
the efficient transfer of this drug across the placenta. The
less severe decrease in glomerular size observed in mice
treated only during postnatal development may also be
related to the time needed to reach steady-state levels of
SC58236, which could require several days because of its
long half-life [19]. The observation that stopping the
drug at P0 results in normalization of glomerular size is
consistent with the possibility of recovery of glomerular
volume from these inhibitory effects in the postnatal
period. The postnatal COX-2 inhibitor sensitivity corre-
sponds to the peak in murine renal COX-2 expression
at P4. We recently reported a similar pattern of COX-2
expression in rat kidney development, with maximal lev-
els between the first and second postnatal week [8].
These studies confirm that as in the rat, rabbit, and
dog [6, 20, 21], renal cortical COX-2 expression in the
mouse is relatively restricted to the cells associated with
the macula densa. Importantly, COX-2 inhibition is not
associated with induction of novel sites of intrarenal
COX-2 expression. Considering the similar glomerular
developmental defect in mice and rats treated with the
COX-2 inhibitor, as well as in mice with a targeted dis-
ruption of the COX-2 gene, and that COX-2 is expressed
in the macula densa in both species, we speculate that
prostanoids or other products resulting from COX-2 ac-
tivity in the macula densa act in a paracrine manner to
influence glomerular development. Although prostan-
oids modulate afferent arteriolar vasoreactivity [22] and
hemodynamic effects could lead to reduced glomerular
volume, the lack of effect of the COX-2 inhibitor admin-
istration on glomerular volume in adult mice argues
against this mechanism. Effects of these prostanoids on
glomerular proliferation and development seem more
likely.
b
Fig. 5. In situ hybridization showing COX-2 mRNA distribution in
mouse renal cortex at P4 (A) and P21 (B). (A and B) Brightfield
illumination of mouse renal cortex at postnatal day 4 (3400). Black
grains depicting hybridization are seen over S-shaped bodies (A). At
this stage of nephron formation, COX-2 mRNA was consistently seen
over cells destined to become tubular epithelial cells. COX-2 mRNA
localizes to the cells of the macula densa (B; P21). Expression in this
structure is seen throughout renal development and in adult kidneys
as well. (C ) In kidneys from mice treated with the COX-2 inhibitor,
COX-2 immunoreactive protein could be localized to cells within and
adjacent to the macula densa (P21).
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The isozyme-specific COX inhibitors used in this study logenesis. No effect of COX-2 inhibitors on glomerular
diameter is observed in adult kidneys. The use of COX-have been characterized previously in vitro and in vivo.
The selectivity of these compounds has been demon- 2–selective inhibitors to prevent premature onset of la-
bor in humans has been proposed [25]. This observationstrated in vivo in rats (SC58560 and SC58236) and mice
(SC58560) [19, 23]. Significant plasma levels for the may have relevance to reports of renal dysgenesis in
human neonates with a history of exposure to NSAIDsCOX-2 inhibitor found in the plasma of the mouse pups
treated postnatally in this study document efficient trans- and should be considered when administering COX-2
inhibitors in the period of renal development in humans.fer of the drug, via milk to the neonatal mice. These levels
have been shown to selectively inhibit COX-2 activity in
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embryonic day; GPAS, glutaraldehyde-periodate acid saline; HPLC,gene disruption with respect to renal development.
high pressure liquid chromatography; NSAIDs, nonsteroidal antiin-These findings also suggest a special role for COX-2 in
flammatory drugs; P, postnatal day; PGE, prostaglandin E; PMSF,
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